logo
XTRA:FYB logo

Formycon Community

XTRA:FYB Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 15 Fair Values set on narratives written by author

Community Investing Ideas

FYB logo
Formycon
AN
AnalystConsensusTarget
Consensus Narrative from 9 Analysts

New Approvals And Regional Expansion Will Create Future Opportunities

Key Takeaways Waiving the Phase III study for FYB206 cuts significant R&D costs, improving net margins and freeing capital for other uses. Strategic regional expansions and targeted product introductions, like the FYB201 syringe, boost market penetration and revenue potential.
View narrative
€49.33
FV
53.3% undervalued intrinsic discount
22.08%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
3 days ago author updated this narrative